Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMABI: Abiraterone Dose Escalation in mCRPC
NCT03458247Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2018
- Primary completion
- Apr 2021
- Countries
- 1
01
Overview
A Phase 2 trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Assistance publique - Hôpitaux de Paris. Started Jun 2018; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03458247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03458247.